In Section C, participants will receive ABBV-744 and oral navitoclax. In Segment D, participants will acquire ABBV-744 and ruxolitinib. Contributors will get treatment till condition progression or perhaps the members are not able to tolerate the study drugs. 88 These preclinical studies supply paradigms for potential clinical trials in AML, https://erichg443seo6.dekaronwiki.com/user